×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NYSE:WST

West Pharmaceutical Services Stock Forecast, Price & News

$301.18
+2.28 (+0.76%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$297.50
$302.10
50-Day Range
$280.61
$372.42
52-Week Range
$275.89
$475.35
Volume
480,976 shs
Average Volume
446,938 shs
Market Capitalization
$22.31 billion
P/E Ratio
33.46
Dividend Yield
0.24%
Price Target
$475.00
30 days | 90 days | 365 days | Advanced Chart

Receive WST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for West Pharmaceutical Services and its competitors with MarketBeat's FREE daily newsletter.

WST Stock Forecast (MarketRank)

Overall MarketRank

2.70 out of 5 stars

Medical Sector

57th out of 1,418 stocks

Fabricated Rubber Products, Not Elsewhere Classified Industry

2nd out of 3 stocks

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
West Pharmaceutical Services logo

About West Pharmaceutical Services (NYSE:WST)

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

WST Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Fabricated rubber products, not elsewhere classified
Sub-Industry
Health Care Supplies
Sector
Medical
CUSIP
95530610
Employees
10,065
Year Founded
1923

Company Calendar

Ex-Dividend for 5/4 Dividend
4/19/2022
Last Earnings
4/28/2022
Dividend Payable
5/04/2022
Today
6/24/2022
Ex-Dividend for 8/3 Dividend
7/19/2022
Dividend Payable
8/03/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$475.00
High Stock Price Forecast
$475.00
Low Stock Price Forecast
$475.00
Forecasted Upside/Downside
+57.7%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$661.80 million
Pretax Margin
26.44%

Debt

Sales & Book Value

Annual Sales
$2.83 billion
Cash Flow
$10.92 per share
Book Value
$31.44 per share

Miscellaneous

Free Float
73,632,000
Market Cap
$22.31 billion
Optionable
Optionable
Beta
1.18

Social Links















West Pharmaceutical Services Frequently Asked Questions

Should I buy or sell West Pharmaceutical Services stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" West Pharmaceutical Services stock.
View analyst ratings for West Pharmaceutical Services
or view top-rated stocks.

What is West Pharmaceutical Services' stock price forecast for 2022?

2 analysts have issued 1 year target prices for West Pharmaceutical Services' shares. Their WST stock forecasts range from $475.00 to $475.00. On average, they predict West Pharmaceutical Services' stock price to reach $475.00 in the next twelve months. This suggests a possible upside of 57.7% from the stock's current price.
View analysts' price targets for West Pharmaceutical Services
or view top-rated stocks among Wall Street analysts.

How has West Pharmaceutical Services' stock price performed in 2022?

West Pharmaceutical Services' stock was trading at $469.01 on January 1st, 2022. Since then, WST shares have decreased by 35.8% and is now trading at $301.18.
View the best growth stocks for 2022 here
.

Are investors shorting West Pharmaceutical Services?

West Pharmaceutical Services saw a decline in short interest during the month of May. As of May 31st, there was short interest totaling 728,100 shares, a decline of 14.4% from the May 15th total of 850,700 shares. Based on an average trading volume of 423,300 shares, the days-to-cover ratio is currently 1.7 days. Approximately 1.0% of the company's shares are sold short.
View West Pharmaceutical Services' Short Interest
.

When is West Pharmaceutical Services' next earnings date?

West Pharmaceutical Services is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for West Pharmaceutical Services
.

How were West Pharmaceutical Services' earnings last quarter?

West Pharmaceutical Services, Inc. (NYSE:WST) announced its earnings results on Thursday, April, 28th. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.18 by $0.12. The medical instruments supplier had revenue of $720 million for the quarter, compared to analysts' expectations of $720.92 million. West Pharmaceutical Services had a trailing twelve-month return on equity of 30.33% and a net margin of 23.76%. West Pharmaceutical Services's revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.05 earnings per share.
View West Pharmaceutical Services' earnings history
.

How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?

West Pharmaceutical Services announced a quarterly dividend on Thursday, April 28th. Shareholders of record on Wednesday, July 20th will be given a dividend of $0.18 per share on Wednesday, August 3rd. This represents a $0.72 dividend on an annualized basis and a yield of 0.24%. The ex-dividend date of this dividend is Tuesday, July 19th.
View West Pharmaceutical Services' dividend history
.

Is West Pharmaceutical Services a good dividend stock?

West Pharmaceutical Services(NYSE:WST) pays an annual dividend of $0.72 per share and currently has a dividend yield of 0.24%. West Pharmaceutical Services has been increasing its dividend for 29 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of West Pharmaceutical Services is 8.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 6.99% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.
View West Pharmaceutical Services' dividend history.

What guidance has West Pharmaceutical Services issued on next quarter's earnings?

West Pharmaceutical Services issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $9.30-$9.45 for the period, compared to the consensus EPS estimate of $9.28. The company issued revenue guidance of $3.05 billion-$3.08 billion, compared to the consensus revenue estimate of $3.07 billion.

Who are West Pharmaceutical Services' key executives?

West Pharmaceutical Services' management team includes the following people:
  • Mr. Eric M. Green, Pres, CEO & Director (Age 52, Pay $3.42M)
  • Mr. Bernard J. Birkett, Sr. VP & CFO (Age 53, Pay $1.5M)
  • Mr. David A. Montecalvo, Sr. VP and Chief Operations & Supply Chain Officer (Age 57, Pay $1.08M) (LinkedIn Profile)
  • Mr. Silji Abraham, Sr. VP & Chief Technology Officer (Age 50, Pay $1.11M) (LinkedIn Profile)
  • Ms. Kimberly Banks MacKay, Sr. VP, Gen. Counsel & Company Sec. (Age 56, Pay $946.43k)
  • Mr. Chad R. Winters, VP, Chief Accounting Officer & Corp. Controller (Age 43)
  • Dr. Quintin J. Lai C.F.A., Ph.D., VP of Strategy & Investor Relations (Age 55)
  • Michele Polinsky, VP of Global Communications
  • Ms. Annette F. Favorite, Chief HR Officer & Sr. VP (Age 57) (LinkedIn Profile)
  • Mr. Richard D. Luzzi, Sr. VP of HR (Age 70)

What is Eric M. Green's approval rating as West Pharmaceutical Services' CEO?

107 employees have rated West Pharmaceutical Services CEO Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among West Pharmaceutical Services' employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

What other stocks do shareholders of West Pharmaceutical Services own?

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

What is West Pharmaceutical Services' stock symbol?

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

Who are West Pharmaceutical Services' major shareholders?

West Pharmaceutical Services' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.77%), BlackRock Inc. (10.91%), State Street Corp (4.58%), APG Asset Management N.V. (3.43%), WCM Investment Management LLC (2.06%) and Brown Advisory Inc. (1.61%). Company insiders that own West Pharmaceutical Services stock include Annette F Favorite, David A Montecalvo, George Lloyd Miller, Patrick J Zenner, Quintin J Lai and Silji Abraham.
View institutional ownership trends for West Pharmaceutical Services
.

Which major investors are selling West Pharmaceutical Services stock?

WST stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Brown Advisory Inc., The Manufacturers Life Insurance Company , Durable Capital Partners LP, Capital Research Global Investors, Northern Trust Corp, Invesco Ltd., and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold West Pharmaceutical Services company stock in the last two years include David A Montecalvo, George Lloyd Miller, Patrick J Zenner, Quintin J Lai, and Silji Abraham.
View insider buying and selling activity for West Pharmaceutical Services
or view top insider-selling stocks.

Which major investors are buying West Pharmaceutical Services stock?

WST stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Fiera Capital Corp, Vanguard Group Inc., Aaron Wealth Advisors LLC, ProShare Advisors LLC, Goldman Sachs Group Inc., Swiss National Bank, and Bank of New York Mellon Corp.
View insider buying and selling activity for West Pharmaceutical Services
or or view top insider-buying stocks.

How do I buy shares of West Pharmaceutical Services?

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is West Pharmaceutical Services' stock price today?

One share of WST stock can currently be purchased for approximately $301.18.

How much money does West Pharmaceutical Services make?

West Pharmaceutical Services (NYSE:WST) has a market capitalization of $22.31 billion and generates $2.83 billion in revenue each year. The medical instruments supplier earns $661.80 million in net income (profit) each year or $9.00 on an earnings per share basis.

How many employees does West Pharmaceutical Services have?

West Pharmaceutical Services employs 10,065 workers across the globe.

Does West Pharmaceutical Services have any subsidiaries?

The following companies are subsidiares of West Pharmaceutical Services: Drug Delivery Assets From Plastef Investissements SA, Medimop Medical Projects Ltd., TGPR Holdings Limited, Tech Group Europe Limited (dba West), Tech Group Grand Rapids Inc. (dba West), The Tech Group Inc., W.P.S.F. Limited, WD SG Pte. Ltd., West Analytical Services LLC, West Contract Manufacturing LLC, West Pharma. Services IL Ltd., West Pharmaceutical Packaging (China) Company Ltd., West Pharmaceutical Packaging India Private Limited, West Pharmaceutical Products Ireland Ltd., West Pharmaceutical Services AZ Inc., West Pharmaceutical Services Argentina S.A., West Pharmaceutical Services Asia Ltd., West Pharmaceutical Services Australia Pty. Ltd., West Pharmaceutical Services Beograd d.o.o., West Pharmaceutical Services Brasil Ltda., West Pharmaceutical Services Colombia S.A.S., West Pharmaceutical Services Cornwall Limited, West Pharmaceutical Services Danmark A/S, West Pharmaceutical Services Delaware Acquisition Inc., West Pharmaceutical Services Deutschland GmbH Co KG, West Pharmaceutical Services France S.A.S., West Pharmaceutical Services Group Limited, West Pharmaceutical Services Hispania S.A., West Pharmaceutical Services Holding Danmark ApS, West Pharmaceutical Services Holding France SAS, West Pharmaceutical Services Holding GmbH, West Pharmaceutical Services Holding II GmbH, West Pharmaceutical Services Holding Ireland North Ltd., West Pharmaceutical Services Holding Ireland South Ltd., West Pharmaceutical Services Holding Japan GK, West Pharmaceutical Services Holdings Ltd., West Pharmaceutical Services Italia S.r.L., West Pharmaceutical Services Korea Ltd., West Pharmaceutical Services Lakewood Inc., West Pharmaceutical Services Normandie SAS, West Pharmaceutical Services Shanghai Medical Rubber Products Co. Ltd., West Pharmaceutical Services Singapore (Holding) Pte. Limited, West Pharmaceutical Services Singapore Pte. Ltd., West Pharmaceutical Services Switzerland GmbH, West Pharmaceutical Services Venezuela C.A., West Pharmaceutical Services Verwaltungs GmbH, West Pharmaceutical Services of Delaware Inc., and West Pharmaceutical Services of Florida Inc..
Read More

When was West Pharmaceutical Services founded?

West Pharmaceutical Services was founded in 1923.

How can I contact West Pharmaceutical Services?

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The official website for West Pharmaceutical Services is www.westpharma.com. The medical instruments supplier can be reached via phone at (610) 594-2900, via email at [email protected], or via fax at 800-345-9800.

This page (NYSE:WST) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.